Serina Therapeutics Inc (SER)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$2.73+1.49%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SER
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 8.8% |
| Our one-year growth estimate | diamond | 100.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 91.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SER — earnings miss
Dated 2026-08-13
and in the press release furnished as Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly s…
Why it matters: Funding is key for operations and growth after recent money losses.
Supportive ifA press release announcing a successful funding round or partnership.
Worry ifNo news or bad news about funding efforts.
Why it matters: Managing costs is key for the company. Big increases can signal trouble.
Worry ifOperating expenses are stable or lower than in past quarters.
Less concerning ifOperating costs rise a lot beyond current trends. This shows poor cost management.
Why it matters: Funding is key for operations and growth. It impacts financial health.
Supportive ifThe company announces a successful funding round of at least $5 million.
Worry ifNo funding announcements are made in the next six months.
Why it matters: The safety review will inform the next dose-escalation decision for SER-252. This is crucial for the study's progress.
Supportive ifThe Safety Monitoring Committee has finished its review. They will move to the next group.
Worry ifThe Safety Monitoring Committee found safety issues. This stops the study.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$325 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $904 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,726 loss on $10,000 · 77.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Financial news will show how the $21.2 million raised helps the company grow.
Watch forOperating costs stay the same or go down while clinical programs move forward.
Also watch forOperating costs go up a lot without progress in clinical programs.
Why it matters: Completing enrollment shows progress in the Phase 1b study for SER-252 in Parkinson's disease.
Supportive ifCohort 1 enrollment for SER-252 is completed by the end of Q3 2026.
Worry ifEnrollment is delayed past the end of Q3 2026.
Why it matters: The safety review will inform the next dose-escalation decision for SER-252. This is critical for the trial's progress.
Supportive ifThe Independent Safety Monitoring Committee says to move forward with the next dose increase. They reviewed Cohort 1.
Worry ifThe Safety Monitoring Committee says not to move forward with the next dose increase.
Why it matters: Financial news will show if the financing improves cash flow. It will also show if it helps operations.
Watch forCash and cash equivalents rise above $23 million, showing better cash flow.
Also watch forCash and cash equivalents decrease or remain stagnant below $23 million.
Why it matters: TFL data will show how well SER-252 works for Parkinson's disease.
Supportive ifTFL data from the SAD study arm is released in the first half of 2027.
Worry ifTFL data release is postponed beyond the first half of 2027.
Why it matters: Addressing compliance issues is crucial for staying listed on the NYSE. Failure to comply could lead to delisting.
Worry ifSerina Therapeutics has a plan to fix its NYSE compliance issues.
Less concerning ifNo progress is made on compliance, leading to potential delisting warnings from the NYSE.
Why it matters: Fixing compliance is important to keep listing status. It also affects investor trust.
Supportive ifManagement has a plan to fix compliance issues in the next quarter.
Worry ifNo progress is reported on compliance issues by the next earnings call.
Why it matters: Securing funding is vital for ongoing operations and growth. Without it, the company may struggle to survive.
Supportive ifSerina Therapeutics has raised at least $5 million in a funding round.
Worry ifNo funding news has been shared. This raises worries about financial health.
Why it matters: This partnership helps develop SER-252 and can improve the company. Success may lead to more progress.
Supportive ifThere are positive updates on the partnership's work in making SER-252.
Worry ifThere are negative news or delays about the partnership with Gannet BioChem.
Why it matters: New partnerships could enhance the value of Serina's POZ Platform and its drug candidates.
Supportive ifLook for news about a new partnership or licensing deal with the POZ Platform.
Worry ifNo new partnerships or licensing deals announced in the next six months.
Why it matters: The recent $21.2 million financing strengthens the balance sheet. It is crucial for ongoing development.
Supportive ifCash and cash equivalents will rise a lot in the next financial report.
Worry ifCash levels drop below $20 million in the next financial report.
Why it matters: Top-line data will show if SER-252 can effectively treat Parkinson's disease. This is crucial for the company's future.
Supportive ifTop-line data from the single-ascending-dose arm is released in the first half of 2027.
Worry ifData release is delayed past the first half of 2027.